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Purpose: Eosinophil count elevations are predictive of adverse outcomes in patients with 
asthma, yet little is known regarding longitudinal eosinophil patterns and their association 
with clinical outcomes. The goal of this study was to assess associations between long-
itudinal persistence of eosinophil elevations and both clinical outcomes and health care 
resource utilization (HCRU).
Methods: Data were extracted from 2 databases in the United Kingdom. Patients included 
were aged ≥13 years, had active asthma, and had ≥3 blood eosinophil count (BEC) record-
ings. Patients were categorized by BEC as: never high (all BEC ≤300 cells/µL), intermit-
tently high (≥1 BEC >300 cells/µL but <75% of BEC >300 cells/µL), or persistently high 
(≥75% of BEC >300 cells/µL). Asthma exacerbations, asthma control (risk domain, overall, 
and full), and HCRU were evaluated for 12 months after the last BEC.
Results: The study population comprised 148,021 patients. Persistently high, intermittently 
high, and never high eosinophil patterns were detected in 13.6%, 40.5%, and 45.9% of 
patients, respectively. Patients with ≥1 elevated BEC were at greater risk for severe asthma 
exacerbations, regardless of whether the elevation was persistent (rate ratio [RR]: 1.28 [95% 
CI 1.24–1.33]; P < 0.001) or intermittent (RR: 1.24 [95% CI 1.21–1.27]; P < 0.001), 
compared with patients with no eosinophil elevations. Full asthma control was achieved by 
<25% of patients across eosinophil pattern groups, and HCRU did not appreciably differ, 
although patients with persistently high BEC had the shortest hospital stay duration among 
the groups.
Conclusion: These data suggest that elevated blood eosinophils, regardless of persistency, 
signify increased risk of severe asthma exacerbations.
Keywords: asthma control, asthma exacerbation, biomarker, eosinophilia, phenotype, type 2 
inflammation
Introduction
Despite the availability of multiple effective treatment options, many patients with 
asthma do not achieve adequate symptom control and are at elevated risk of flare- 
ups (exacerbations).1–3 Exacerbations can be life-threatening and contribute to 
disease-related morbidity, impaired health-related quality of life, progressive loss 
of lung function, and higher health care resource utilization (HCRU).4,5 Moreover, 
standard treatment of exacerbations involves oral corticosteroids (OCS), which are 
associated with risk of acute and chronic adverse events as well as increased HCRU 
and costs.6,7 Characterizing patient-related and clinical parameters that are 
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associated with uncontrolled asthma and exacerbation risk 
has the potential to improve outcomes by identifying 
patients who require additional monitoring and therapeutic 
intervention.8–10 Moreover, understanding asthma etiology 
at the individual level enhances the ability to implement 
targeted treatment,1,11 thereby augmenting the likelihood 
of achieving asthma control.
Asthma is not a monolithic condition, rather it is 
a heterogeneous disease with varied etiologic 
underpinnings.2,11 Eosinophil elevations measured in sputum 
or blood denote a particular asthma endotype, eosinophilic 
asthma, which is driven by eosinophilic airway 
inflammation.2,11,12 High blood eosinophil counts (BECs) 
are linked to multiple adverse outcomes in patients with 
asthma, including increased risk for exacerbations, severe 
exacerbations, asthma-related hospital readmissions, and 
poor asthma control.13–19 In an historical cohort of patients 
with asthma from the United Kingdom (UK), a BEC >400 
cells/µL conferred a 42% greater risk of severe exacerba-
tions, a 28% greater risk of acute respiratory events, and 
a 26% lower likelihood of achieving asthma control during 
a 1-year follow-up period compared with patients whose 
BECs were ≤400 cells/µL.15 Moreover, exacerbation rates 
demonstrated a dose-response relationship with BECs start-
ing at a reference category of ≤200 cells/µL. The compara-
tively small proportion of patients with severe, uncontrolled 
eosinophilic asthma accounts for a disproportionate share of 
asthma-related HCRU and costs.20,21 In a population-based 
analysis conducted in the UK, patients with severe, uncon-
trolled, eosinophilic asthma comprised <1% of the study 
population, yet accounted for 2.5 to 7.6 times greater 
HCRU and direct asthma-related costs than the general 
population.21
In clinical practice, BEC assessments for the identifica-
tion of eosinophilic asthma are infrequently considered 
and, when applied, are often limited to a single time 
point. This approach may provide an incomplete picture 
because BEC levels are not fixed over time.22–26 Indeed, 
eosinophil counts in sputum or blood samples of patients 
with asthma have been shown to vary appreciably in 
sequential measurements.22,23,25 Few studies, particularly 
those derived from real-world data, have parsed asthma 
endotypes by longitudinal persistence of BEC elevations, 
and it is not known whether persistence of BEC elevations 
is associated with health outcomes. This study was per-
formed to characterize patients with varying degrees of 
persistence in BEC elevation and to assess the association 
of eosinophil elevation patterns with clinical outcomes and 
HCRU in patients with asthma.
Methods
Data Source and Study Design
Data were extracted from the Optimum Patient Care 
Research Database (OPCRD) and the Clinical Practice 
Research Datalink (CPRD) GOLD database. OPCRD 
comprises data obtained through the Optimum Patient 
Care Quality Improvement services, which contains infor-
mation from both anonymized electronic medical records 
(EMRs) and patient responses to disease-specific question-
naires. At data extraction, OPCRD contained data for 
approximately 10 million patients from more than 700 
practices in the UK. CPRD GOLD is a primary care 
database of anonymized medical records that includes 
data for more than 11 million patients from 674 general 
practices in the UK.27 Data obtained from CPRD were 
limited to patients whose records could be linked to 
Hospital Episode Statistics, a comprehensive source for 
hospital admission and outpatient HCRU data. Patient- 
level data from OPCRD and CRPD are de-identified at 
the source, and patients have the option to opt-out of 
sharing their health information.
Baseline data represented the 12 months prior to the 
index date, defined as the most recent BEC measurement 
for which there were ≥12 months of subsequent outcomes 
data (Figure 1). Asthma outcomes and HCRU were eval-
uated for 12 months after the index date (the 
outcome year). The year of the index date for patients 
included in the data sets ranged from 2006 to 2018.
Study Population
For inclusion in the study, patients were required to be 
aged ≥13 years on the index date and have: a diagnostic 
code for asthma recorded at any time that was not fol-
lowed by a code that asthma was resolved; ≥3 BECs 
recorded after the date of first asthma diagnosis; active 
asthma, defined as ≥1 prescription for an inhaler contain-
ing an inhaled corticosteroid (ICS) or a short-acting 
β2-agonist (SABA) in the 12 months before the index 
date; and continuous EMR data for 12 months prior to 
and 12 months after the index date. Patients were excluded 
if they had a diagnosis of chronic lower respiratory disease 
other than asthma or chronic obstructive pulmonary dis-
ease (COPD) or if there was uncertain information regard-
ing the age of asthma onset. Age of asthma onset was 
https://doi.org/10.2147/JAA.S306416                                                                                                                                                                                                                                   
DovePress                                                                                                                                                      
Journal of Asthma and Allergy 2021:14 728
Tran et al                                                                                                                                                              Dovepress
































































defined as first recording of asthma diagnosis dated in the 
first 3 years of electronic medical recording or in the 
fourth or fifth year of electronic medical recording not 
preceded or followed by an inhaler treatment prescription 
within 90 days after that date.
Measurements and Outcomes
Blood Eosinophil Counts
Patients were categorized by longitudinal patterns of BEC 
elevations as: never high (all BECs ≤300 cells/µL), intermit-
tently high (≥1 BEC >300 cells/µL but <75% of BECs >300 
cells/µL), or persistently high (≥75% of BECs >300 cells/ 
µL). To qualify as persistently high, patients with 3 measure-
ments were not allowed to have any BEC ≤300 cells/µL, 
patients with 4–7 measurements were allowed to have only 1 
BEC ≤300 cells/µL, patients with 8–11 measurements were 
allowed to have 2 BECs ≤300 cells/µL, patients with 12–15 
measurements were allowed to have 3 BECs ≤300 cells/µL, 
patients with 16–19 measurements were allowed to have 4 
BECs ≤300 cells/µL, and patients with 20–23 measurements 
were allowed to have 5 BECs ≤300 cells/µL. Blood eosino-
phil counts ≤300 cells/μL that were measured during anti- 
interleukin-5 therapy or ≤4 weeks after an OCS prescription 
(0.2% of values) were not considered valid, as the counts 
may have been reduced by therapy.
Baseline Asthma Disease Burden
Characteristics of asthma examined during the 
baseline year included Global Initiative for Asthma 
(GINA) step of asthma management according to 201828 
and 201929 definitions, medication use, severe asthma 
exacerbations, acute respiratory events, and symptom 
control metrics. A severe asthma exacerbation was defined 
according to American Thoracic Society/European 
Respiratory Society criteria30 as an asthma-related hospi-
talization or emergency department (ED) visit and/or 
a prescription for acute OCS. An acute respiratory event 
was defined as an asthma-related hospitalization or ED 
visit, a prescription for acute OCS, and/or a prescription 
for antibiotics in conjunction with an asthma-related pri-
mary care consultation. Baseline symptom control, mea-
sured in patients with an annual asthma review within 15 
months of the baseline period, was scored from 0 to 3 
based on Royal College of Physicians questions for 
asthma.31 Poor symptom control was characterized by 
the presence of any 3 of following symptoms: difficulty 
sleeping due to asthma, usual asthma symptoms during 
the day (cough, wheeze, chest tightness, or breathless-
ness), interference of asthma with usual activities, or >2 
puffs of SABA prescribed per week on average over the 
baseline year. Uncontrolled asthma in patients treated at 
GINA step 4 or treatment at GINA step 5 irrespective of 
control status was categorized as difficult-to-treat asthma.
Asthma Outcomes
Asthma outcomes were evaluated during the 12 months after 
the index date and included severe asthma exacerbations, 
acute respiratory events, and measures of asthma control. 
Severe asthma exacerbations were based on data from 
CPRD and were defined as a hospitalization with asthma as 
the primary diagnosis, a respiratory-related ED visit, pre-
scription for acute OCS, and/or an EMR recording of an 
acute exacerbation. An acute respiratory event was defined 
as a hospitalization with asthma as the primary diagnosis, 
Figure 1 Study design. Patients were categorized as persistently high, intermittently high, or never high based on blood eosinophil counts (BECs) from the first asthma 
diagnosis to the index date. The index date was the date of the last BEC with at least 12 months’ outcome data and without prescriptions for oral corticosteroids or anti- 
interleukin-5 therapy in the prior 4 weeks. The baseline and outcome years were 1 year prior to and 1 year after the index date. 
Abbreviation: HCRU, health care resource utilization.
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a respiratory-related ED visit, a prescription for acute OCS, 
an EMR recording of an acute exacerbation, and/or prescrip-
tion for antibiotics in conjunction with an asthma-related 
primary care consultation. Asthma control was assessed by 
3 measures: risk domain asthma control (RDAC), overall 
asthma control, and full asthma control. Patients achieved 
RDAC if they had neither an acute respiratory event nor 
a respiratory-related outpatient visit during the 
outcome year. Overall asthma control required attainment 
of RDAC and that the patient was receiving an average 
daily dose of ≤200-μg salbutamol/≤500-μg terbutaline.32 
Full asthma control was defined as the absence of frequent 
(≥2) OCS course prescriptions, respiratory hospital admis-
sion, ED visit, or poor symptom control.
Health Care Resource Utilization
HCRU was measured for 12 months after the index date 
using data from CPRD and included physician office vis-
its, outpatient visits, ED visits, and hospital admissions 
(all-cause, asthma as the primary diagnosis, asthma at 
any diagnostic position, and a respiratory condition as 
the primary diagnosis).
Statistical Analysis
Descriptive statistics were reported for all variables. Due to 
its log-normal distribution, geometric means and geometric 
standard deviations were calculated for BECs. To examine 
statistical significance of differences in distribution of char-
acteristics among the endotypes, Pearson’s chi-square tests of 
independent categories for categorical variables and the non- 
parametric Kruskal–Wallis equality-of-populations rank test 
for variables on a continuous or ordinal scale were per-
formed. Relevant differences in crude distribution of char-
acteristics between longitudinal eosinophil pattern groups 
were reported as the standardized mean difference (SMD) 
with the persistently high group as the reference. The SMD is 
not affected by the number of observations and provides 
information on the magnitude of differences and is, therefore, 
more informative than P values for these types of analyses.33 
An SMD >10% indicates a relevant difference.
To study the association between eosinophil pattern and 
asthma control after adjustment for potential confounders, 
negative binomial regression analyses were performed with 
the number of severe exacerbations in the outcome year as the 
outcome variable. For these analyses, the EMR-based defini-
tion of severe exacerbation was used in the full population of 
patients (OPCRD+CPRD). Covariates tested in the model 
included number of BECs available, mean annual rate of 
BEC measurements, sex, age, smoking habits, and presence 
of comorbidities. Covariates were considered relevant con-
founders if they changed the association coefficient by ≥5%. 
Rate ratios and 95% confidence intervals after adjustment for 
confounders are reported. Statistical analyses were performed 
using Stata MP/6 version 15.1 (StataCorp LLC, College 
Station, Texas, USA).
Results
A total of 148,021 patients were eligible for inclusion in 
the study population: 77,715 patients from OPCRD and 
70,306 from CPRD (Figure 2). The mean age was 56.0 ± 
17.7 years, and 68.5% of patients were women. The med-
ian interval between asthma diagnosis and the index date 
was 15 years (interquartile range [IQR], 9–24 years).
Blood Eosinophil Counts
Patients had a median of 6 (IQR, 4–10) BEC measurements 
recorded during the study interval, with a median of 0.84 
(IQR, 0.54–1.28) measurements per individual follow-up 
year. Persistently high BECs (≥75% of counts >300 cells/ 
µL) were detected in 13.6% of patients, intermittently high 
(≥1 count and <75% of counts >300 cells/µL) in 40.5% of 
patients, and never high in 45.9% of patients. The proportion 
of patients with no high eosinophil recording decreased with 
the number of available eosinophil measurements, resulting 
in a larger proportion of patients in the intermittently high 
group as the number of measurements increased from the 
minimum of 3 (Figure 3). The percentage of patients in the 
persistently high group varied only modestly for patients 
with 6 or more BEC measurements.
The persistently high group had a lower mean age and 
a greater proportion of male patients compared with the 
intermittently high and never high groups (SMD >10% for 
all comparisons; Table 1). These patients also had a higher 
prevalence of nasal polyps and allergic rhinitis but a lower 
prevalence of anxiety/depression than the other 2 groups 
(Tables 1 and 2). Overall, the burden of comorbidities, as 
measured by the Charlson comorbidity index, was lower for 
patients categorized as persistently high vs intermittently 
high (SMD = 12.7%).
Asthma Severity During the Baseline 
Period
GINA step of asthma management was not appreciably 
more advanced in patients in the persistently high group 
compared with the intermittently high group (Table 3). 
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However, moderate to severe asthma (GINA step 3–5) was 
more common in the intermittently (59.0%) or persistently 
high (61.2%) groups than in the never high group (54.0%). 
Consistent with the inclusion criteria, the majority of 
patients in all groups were receiving ICS. The proportion 
of patients not receiving ICS decreased from 19.9% in the 
never high group to 17.2% in the intermittently high group 
and 14.9% in the persistently high group. Less excessive 
SABA use (>300 µg mean daily salbutamol equivalent) 
was observed in the never high group (30.0%) vs the 
intermittently (35.0%) or persistently high (36.6%) groups. 
Maintenance OCS use was not meaningfully different 
between treatment groups, but the number of patients 
with a mean daily dose >7.5 mg was higher in the 
Figure 2 Patient selection criteria. 
Abbreviations: BEC, blood eosinophil count; CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics; OCS, oral corticosteroid; OPCRD, Optimum 
Patient Care Research Database.
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intermittent group (1.2%) than in the persistent (0.6%) and 
never high groups (0.7%).
Asthma Control During the Outcome 
Year
A greater percentage of patients with ≥1 BEC >300 cells/ 
µL (persistently high, 26.0%; intermittently high, 25.7%) 
experienced ≥1 severe asthma exacerbation during the 
outcome year compared with the never high group 
(21.7%; Table 4). Other measures of asthma control were 
not appreciably different among blood eosinophil pattern 
groups. Full asthma control was achieved by 22.3%, 
24.3%, and 23.6% of patients in the persistently high, 
intermittently high, and never high groups, respectively.
After adjustment for confounders, patients in the per-
sistently high and intermittently high groups had similarly 
elevated severe exacerbation risk compared with the never 
high group (Table 5). A history of nasal polyps, older age, 
anxiety or depression, rate of BEC measurements per year, 
and overall number of measurements available were inde-
pendent predictors of increased severe exacerbation risk 
(P < 0.001 for all comparisons). Smoking status signifi-
cantly modified the association between blood eosinophil 
patterns and severe exacerbation risk (P < 0.001; Figure 
4). Patients who never smoked and had persistently high 
BECs had a 47% greater risk of severe exacerbations 
compared with never smokers in the never high group. 
The increase in the intermittently high group was 27% 
relative to the never high group. For ex-smokers, 
a similar increase in risk was found in the persistently 
high and intermittently high groups (32% and 28%, 
respectively). Current smokers had a diminished, but sig-
nificant, increase in severe exacerbation risk associated 
with persistently or intermittently high BECs.
Health Care Resource Utilization During 
the Outcome Year
The mean number of all-cause general practitioner con-
sultations was greater in the intermittently high group vs 
the never high or persistently high groups (SMD = 15.1%); 
this trend was not observed for respiratory condition- 
related visits (Table 6). Hospital admissions due to asthma 
or a respiratory condition as the primary diagnosis were 
rare events and not meaningfully different among groups. 
Within the small population of patients with an asthma- 
related hospital admission, those with persistently high 
BECs had a shorter mean length of stay (4.7 ± 7.6 days) 
than the never high (8.0 ± 12.2 days; SMD = 32.8%) and 
intermittently high patients (6.9 ± 11.2 days; SMD = 
23.1%). Similar results were found for inpatient admis-
sions with a respiratory condition as the primary diagnosis.
Discussion
Results from this large observational cohort highlight the 
role of eosinophil elevations as a prognostic marker of 
asthma exacerbation risk. Among patients with at least 3 
BEC measures, those with at least 1 elevated BEC (ie, 
BEC >300 cells/µL), regardless of whether the elevation 
was persistent or intermittent, were at greater risk for 
severe asthma exacerbations compared with patients with 
no BECs >300 cells/µL. Moreover, risk was increased to 
a similar degree in patients with persistently or intermit-
tently high BECs. These findings imply that a single high 
eosinophil measurement is sufficient to identify patients 
with elevated risk of severe asthma exacerbations.
In this data set, persistently high BEC was present in 
13.6% of patients, whereas either persistently or intermit-
tently high BEC was detected in 54.1% of the study popula-
tion. These data are consistent with a prior longitudinal study 
of sequential sputum samples taken during routine clinic 
visits in which 29% of children with mild to moderate asthma 
had elevated eosinophil counts in all samples and 24% had 
a mixture of sputum samples that were eosinophilic and non- 
eosinophilic.22 In previous studies where a single measure-
ment was used to categorize eosinophil elevations,13,21 the 
Figure 3 Distribution of longitudinal eosinophil patterns by the number of blood 
eosinophil measurements available. The proportion of patients classified as persis-
tently high, intermittently high, or never high are shown by total number of blood 
eosinophil count (BEC) measurements available.
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Table 1 Patient Demographics and Baseline Characteristics
Parameter Never High 
(N = 67,980)
Intermittently High  
(N = 59,894)
Persistently High  
(N = 20,147)
Mean age, years ± SDa,b 56.2 ± 17.2 56.5 ± 18.0 53.9 ± 18.6
Male, n (%)a,b 18,775 (27.6) 19,803 (33.1) 8,070 (40.1)
Smoking status, n (%)
N 64,973 57,547 19,288
Never smoker 23,636 (36.4) 20,362 (35.4) 7572 (39.3)
Current smoker 10,160 (15.6) 8423 (14.6) 2777 (14.4)
Ex-smoker 31,177 (48.0) 28,762 (50.0) 8939 (46.3)
BMI, n (%)
N 64,500 57,065 18,931
<18.5 kg/m2 1086 (1.7) 1150 (1.9) 451 (2.4)
≥18.5 to <25 kg/m2 16,798 (26.0) 14,884 (26.1) 5278 (27.9)
≥25 to <30 kg/m2 21,338 (33.1) 18,818 (33.0) 6356 (33.6)
≥30 kg/m2 25,278 (39.2) 22,258 (39.0) 6846 (36.2)
Mean number of BECs ± SDb 7.7 ± 7.6 10.5 ± 11.7 7.7 ± 7.3
Median (IQR) 6.0 (4.0, 9.0) 7.0 (5.0, 12.0) 5.0 (4.0, 9.0)
Mean number of BECs per year ± SDb 1.0 ± 0.9 1.2 ± 1.2 1.0 ± 0.9
Geometric mean BEC at index date, cells/µL ± SDa,b 125.9 ± 2.0 251.2 ± 2.0 501.2 ± 1.6
BEC category, n (%)a,b
<150 cells/µL 36,122 (53.1) 9291 (15.5) 281 (1.4)
150–300 cells/µL 31,868 (46.9) 31,288 (52.2) 1631 (8.1)
>300 cells/µL NA 19,315 (32.2) 18,235 (90.5)
Age of asthma onset, n (%)a
Childhood (<18 yrs) 14,668 (21.6) 15,316 (25.6) 5674 (28.2)
Adult (18–29 yrs) 8288 (12.2) 7591 (12.7) 2619 (13.0)
Late-onset (≥30 yrs) 45,024 (66.2) 36,987 (61.8) 11,854 (58.8)
History of nasal polyps, n (%)a,b 1255 (1.8) 3028 (5.1) 2167 (10.8)
Charlson comorbidity index, n (%)b
N 66,188 58,444 19,651
0–1 46,335 (70.0) 38,131 (65.2) 13,913 (70.8)
2–3 14,526 (21.9) 14,044 (24.0) 4176 (21.3)
≥4 5327 (8.0) 6269 (10.7) 1562 (7.9)
Maintenance OCSc in baseline year, n (%) 489 (0.7) 743 (1.2) 126 (0.6)
Ever used anti-interleukin-5 therapy, n (%) <5 <5 <5
Severe exacerbations according to EMR during the baseline year, mean ± 
SD
0.42 ± 1.16 0.57 ± 1.44 0.52 ± 1.30
Severe exacerbationsd in baseline year, n (%)a
0 53,172 (78.2) 44,165 (73.7) 14,857 (73.7)
1 9185 (13.5) 8955 (15.0) 3124 (15.5)
2 2929 (4.3) 3187 (5.3) 1028 (5.1)
3 1114 (1.6) 1288 (2.2) 499 (2.5)
≥4 1580 (2.3) 2299 (3.8) 639 (3.2)
Notes: P < 0.001 for tests of independence/equality of populations for all categories except use of anti-interleukin-5 therapy. aStandardized mean difference (SMD) >10% for 
comparison of never high and persistently high. bSMD >10% for comparison of intermittently high and persistently high. cMaintenance OCS use was determined using an algorithm that 
took into account the dosing instructions, daily dosage, strength of prescription, number of prescriptions, and concurrent diagnostic codes that would indicate acute rather than 
maintenance use. dA severe exacerbation in the baseline year was defined as an asthma-related hospitalization or emergency department visit and/or a prescription for acute OCS. 
Abbreviations: BEC, blood eosinophil count; BMI, body mass index; EMR, electronic medical record; IQR, interquartile range; NA, not applicable; OCS, oral 
corticosteroid; SD, standard deviation.
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proportion of patients with high BEC (≥300 cells/µL) was 
lower (33% to 43%), likely reflecting the decreased detection 
of BEC elevations when only 1 measurement was used 
versus the minimum of 3 measurements required in the 
current study. The comparable increase in the risk of severe 
exacerbations in the intermittently high and persistently high 
BEC groups observed in our study underscores the need to 
identify patients in both groups.
Despite the similar risk of severe exacerbations in the 
persistently high and intermittently high BEC groups, 
there were notable areas of divergence. Compared with 
the intermittently high group, patients in the persistently 
high group had a greater prevalence of nasal polyps (5.1% 
vs 10.8%), a condition known to be associated with eosi-
nophil elevations34 and an independent predictor of severe 
asthma exacerbation risk in our analysis. For patients who 
Table 2 Distribution of Comorbidities by Longitudinal Eosinophil Pattern
Variable Never High (N= 67,980) Intermittently High (N= 59,894) Persistently High (N= 20,147)
Eczemaa
No, n (%) 49,854 (73.3) 41,129 (68.7) 13,647 (67.7)
Yes, inactive, n (%) 12,738 (18.7) 12,392 (20.7) 3880 (19.3)
Yes, active, n (%) 5388 (7.9) 6373 (10.6) 2620 (13.0)
Allergic rhinitisa,b
No, n (%) 47,167 (69.4) 38,229 (63.8) 12,011 (59.6)
Yes, inactive, n (%) 12,378 (18.2) 12,273 (20.5) 4197 (20.8)
Yes, active, n (%) 8435 (12.4) 9392 (15.7) 3939 (19.6)
Urticaria ever, n (%) 5659 (8.3) 5944 (9.9) 1969 (9.8)
Food allergy ever, n (%) 1345 (2.0) 1521 (2.5) 679 (3.4)
Anaphylaxis ever, n (%) 364 (0.5) 427 (0.7) 153 (0.8)
Aspirin sensitivity ever, n (%) 877 (1.3) 925 (1.5) 229 (1.1)
Chronic rhinosinusitisa
No, n (%) 60,184 (88.5) 51,596 (86.1) 16,990 (84.3)
Yes, without nasal polyps, n (%) 7375 (10.8) 7111 (11.9) 2234 (11.1)
Yes, with nasal polyps, n (%) 421 (0.6) 1187 (2.0) 923 (4.6)
COPD ever, n (%) 5576 (8.2) 5559 (9.3) 1563 (7.8)
GERD ever, n (%) 14,231 (20.9) 13,020 (21.7) 3587 (17.8)
Diabetes mellitus ever, n (%) 8181 (12.0) 9390 (15.7) 2769 (13.7)
Osteoporosis ever, n (%) 3365 (4.9) 3155 (5.3) 804 (4.0)
Hypertension ever, n (%) 23,072 (33.9) 21,395 (35.7) 6311 (31.3)
Cardiovascular disease ever, n (%)b 13,312 (19.6) 13,274 (22.2) 3637 (18.1)
Ischemic heart disease ever, n (%) 5910 (8.7) 6393 (10.7) 1846 (9.2)
Heart failure ever, n (%) 1324 (1.9) 1539 (2.6) 383 (1.9)
Myocardial infarction ever, n (%) 2085 (3.1) 2624 (4.4) 847 (4.2)
CKD, stage 3–5 ever, n (%) 5391 (7.9) 6058 (10.1) 1704 (8.5)
Anxiety/depression ever, n (%)a,b 33,671 (49.5) 29,179 (48.7) 8441 (41.9)
Apnea ever, n (%) 1069 (1.6) 1136 (1.9) 334 (1.7)
Pneumonia diagnosis ever, n (%) 3572 (5.3) 3766 (6.3) 1135 (5.6)
Notes: P <0.001 for tests of independence for all categories. aStandardized mean difference (SMD) >10% for comparison of never high and persistently high. bSMD >10% for 
comparison of intermittently high and persistently high. 
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease.
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Table 3 Distribution of Asthma Therapy in the Baseline Year by Longitudinal Eosinophil Pattern
Variable Never High (N = 67,980) Intermittently High  
(N = 59,894)
Persistently High  
(N = 20,147)
GINA step (2019), n (%)a, †
1 12,884 (19.0) 9742 (16.3) 2836 (14.1)
2 18,377 (27.0) 14,805 (24.7) 4986 (24.7)
3 11,657 (17.1) 10,173 (17.0) 3500 (17.4)
4 14,552 (21.4) 13,876 (23.2) 4978 (24.7)
5 10,510 (15.5) 11,298 (18.9) 3847 (19.1)
GINA step (2018), n (%)a, †
1 12,884 (19.0) 9742 (16.3) 2836 (14.1)
2 18,377 (27.0) 14,805 (24.7) 4986 (24.7)
3 12,663 (18.6) 11,123 (18.6) 3845 (19.1)
4 23,778 (35.0) 23,766 (39.7) 8397 (41.7)
5 278 (0.4) 458 (0.8) 83 (0.4)
Last ICS management step, n (%)a, †
No ICS 13,529 (19.9) 10,279 (17.2) 2995 (14.9)
Low-dose ICS monotherapy 19,652 (28.9) 15,904 (26.6) 5318 (26.4)
Low-dose ICS/LABA 5495 (8.1) 5273 (8.8) 1893 (9.4)
Medium-dose ICS monotherapy 6370 (9.4) 5326 (8.9) 1714 (8.5)
Medium-dose ICS/LABA 15,895 (23.4) 15,443 (25.8) 5512 (27.4)
High-dose ICS monotherapy 503 (0.7) 565 (0.9) 249 (1.2)
High-dose ICS/LABA 6526 (9.6) 7087 (11.8) 2460 (12.2)
Triple therapy inhaler 10 (0.0) 17 (0.0) 6 (0.0)
ICS, mean daily dose FP equivalent (µg)
Mean ± SD† 381.8 ± 639.1 406.1 ± 649.7 415.0 ± 667.1
Median (IQR) 164.0 (33.0, 439.0) 193.0 (55.0, 484.0) 197.0 (55.0, 477.0)
ICS dose category, n (%)a, †
0 13,532 (19.9) 10,284 (17.2) 2995 (14.9)
1 12,552 (18.5) 10,621 (17.7) 3679 (18.3)
2 10,843 (16.0) 9696 (16.2) 3460 (17.2)
3 16,390 (24.1) 15,263 (25.5) 5352 (26.6)
4 14,663 (21.6) 14,030 (23.4) 4661 (23.1)
ICS possession ratio during the baseline year (%)
N (% non-missing) 54,448 (80.1) 49,610 (82.8) 17,152 (85.1)
Mean ± SD† 74.4 ± 54.4 73.5 ± 53.4 71.0 ± 50.8
Median (IQR) 66.0 (33.0, 100.0) 64.0 (34.0, 99.0) 62.0 (34.0, 96.0)
ICS possession ratio category, n (%)†
<50 20,591 (37.8) 18,829 (38.0) 6711 (39.1)
50–69 8312 (15.3) 8015 (16.2) 2874 (16.8)
70–79 3529 (6.5) 3263 (6.6) 1200 (7.0)
≥80 22,016 (40.4) 19,503 (39.3) 6367 (37.1)
Number of ICS inhalers for 30 days dispensed in baseline year
Mean ± SD† 7.3 ± 6.9 7.4 ± 6.8 7.4 ± 6.4
Median (IQR) 6.0 (2.0, 11.0) 6.0 (2.0, 11.0) 6.0 (3.0, 11.0)
ICS inhaler category, n (%)†
0 11,353 (16.7) 8832 (14.7) 2560 (12.7)
1–3 12,933 (19.0) 11,155 (18.6) 3713 (18.4)
4–6 11,681 (17.2) 11,116 (18.6) 4066 (20.2)
(Continued)
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never smoked, persistently high BEC was associated with 
a significantly greater risk of severe exacerbations com-
pared with the intermittently high group. Risk of severe 
exacerbations was also greater in the persistently high and 
intermittently high groups relative to the never high group 
in current and former smokers, although the magnitude of 
risk increase was similar in the persistently high and 
intermittently high groups. In a prior analysis of CPRD 
data, an association was detected between a high BEC 
recorded within 1 year before hospital admission for 
asthma and increased risk of rehospitalization during the 
subsequent year in nonsmokers but not in current 
smokers.19 These data suggest that smoking may modify 
the relationship between BEC elevations and exacerbation 
Table 3 (Continued). 
Variable Never High (N = 67,980) Intermittently High  
(N = 59,894)
Persistently High  
(N = 20,147)
7–9 9347 (13.7) 8724 (14.6) 3237 (16.1)
>9 22,666 (33.3) 20,067 (33.5) 6571 (32.6)
SABA, mean daily dose salbutamol equivalent (µg)a
N (% non-missing) 60,836 (89.5) 54,468 (90.9) 18,381 (91.2)
Mean ± SD† 270.0 ± 427.5 318.4 ± 534.8 321.1 ± 485.3
Median (IQR) 164.0 (55.0, 329.0) 164.0 (55.0, 438.0) 164.0 (55.0, 438.0)
SABA dose category, n (%)a, †
0 10,083 (16.6) 8259 (15.2) 2606 (14.2)
1–100 10,110 (16.6) 7947 (14.6) 2615 (14.2)
101–200 14,205 (23.3) 11,962 (22.0) 4006 (21.8)
201–300 8193 (13.5) 7221 (13.3) 2428 (13.2)
301–400 5501 (9.0) 5188 (9.5) 1885 (10.3)
>400 12,744 (20.9) 13,891 (25.5) 4841 (26.3)
OCS, mean daily dose ± SD (mg)† 0.3 ± 1.4 0.5 ± 1.9 0.4 ± 1.5
OCS dose category, n (%)†
0 53,225 (78.3) 44,127 (73.7) 14,857 (73.7)
>0 to <2.5 12,700 (18.7) 12,855 (21.5) 4563 (22.6)
≥2.5 to <5 1206 (1.8) 1578 (2.6) 432 (2.1)
≥5 to <7.5 371 (0.5) 620 (1.0) 167 (0.8)
≥7.5 478 (0.7) 714 (1.2) 128 (0.6)
SAMA ≥1 prescription, n (%)† 1450 (2.1) 1425 (2.4) 405 (2.0)
LAMA ≥1 prescription, n (%)† 3886 (5.7) 4148 (6.9) 1115 (5.5)
LABA ≥1 prescription, n (%)* 3243 (4.8) 2936 (4.9) 899 (4.5)
Theophylline ≥1 prescription, n (%)† 732 (1.1) 1039 (1.7) 391 (1.9)
LTRA ≥1 prescription, n (%)† 4570 (6.7) 4680 (7.8) 1836 (9.1)
Chromones ≥1 prescription, n (%) 35 (0.1) 34 (0.1) 16 (0.1)
Biologics ≥1 prescription, n (%) <5 <5 <5
Anti-IgE therapy ever ≥1 prescription, n (%) <5 <5 <5
Anti-IL5 therapy ever ≥1 prescription, n (%)* <5 <5 <5
Anti-IL4 therapy ever ≥1 prescription, n (%) <5 <5 <5
Notes: *P < 0.05; †P ≤ 0.001 for tests of independence/equality of populations. aStandardized mean difference >10% for comparison of never high and persistently high. 
Abbreviations: FP, fluticasone propionate; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IgE, immunoglobulin E; IL, interleukin; IQR, interquartile range; 
LABA, long-acting β-agonist; LAMA, long-acting muscarinic receptor antagonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β2- 
agonist; SAMA, short-acting muscarinic receptor antagonist; SD, standard deviation.
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Table 5 Association Between Eosinophil Pattern and the Rate of Exacerbations During the Outcome Year
Variable Category Rate Ratio (95% CI) P value
Persistence of BEC elevation No high BEC Reference
Persistently high BEC 1.28 (1.24–1.33) < 0.001
Intermittently high BEC 1.24 (1.21–1.27) < 0.001
Confounders
Nasal polyps No Reference
Yes 1.36 (1.33, 1.39) < 0.001
Age per 10 years 1.28 (1.23–1.33) < 0.001
Age2 per 10 years 0.99 (0.99–0.99) < 0.001
Anxiety/depression No Reference
Yes 1.36 (1.33–1.39) < 0.001
Rate of BEC measurements per year 1.23 (1.21–1.25) < 0.001
Number of BEC measurements 1.01 (1.00–1.01) < 0.001
Note: Negative binomial regression analysis was performed with the number of exacerbations in the outcome year as the outcome variable and number of blood eosinophil 
counts available, mean annual rate of blood eosinophil count measurements, sex, age, smoking habits, and presence of comorbidities as covariates. 
Abbreviations: BEC, blood eosinophil count; CI, confidence interval.
Table 4 Asthma Control During the Outcome Year by Longitudinal Eosinophil Pattern
Parameter Never High (N = 32,894) Intermittently High  
(N = 27,966)
Persistently High  
(N = 9446)
Severe asthma exacerbationsa mean ± 
SD
0.41 ±1.15 0.56 ± 1.47 0.53 ± 1.29
Severe asthma exacerbation category,  
n(%)b
None, n (%) 25,744 (78.3) 20,792 (74.3) 6989 (74.0)
1, n (%) 4471 (13.6) 4079 (14.6) 1418 (15.0)
2, n (%) 1390 (4.2) 1429 (5.1) 498 (5.3)
3, n(%) 546 (1.7) 624 (2.2) 228 (2.4)
≥ 4, n (%) 743 (2.3) 1042 (3.7) 313 (3.3)
Acute lower respiratory events, mean ± 
SD
0.74 ± 1.52 0.92 ± 1.83 0.83 ± 1.58
Acute lower respiratory event category, 
n (%)
None, n (%) 20,767 (63.1) 16,787 (60.0) 5688 (60.2)
1, n (%) 7096 (21.6) 5947 (21.3) 2084 (22.1)
2, n (%) 2531 (7.7) 2369 (8.5) 817 (8.6)
3, n (%) 1059 (3.2) 1041 (3.7) 354 (3.7)
≥ 4, n (%) 1441 (4.4) 1822 (6.5) 503 (5.3)
Risk Domain Asthma Control, n (%)c 20,331 (61.8) 16,396 (58.6) 5534 (58.6)
Overall asthma control, n (%)d 3809 (11.6) 2774 (9.9) 910 (9.6)
Full asthma control, n (%)e 7776 (23.6) 6782 (24.3) 2107 (22.3)
Notes: P < 0.001 for tests of independence/equality of populations for all categories. aA severe asthma exacerbation during the outcome year was defined as a hospitalization with 
asthma as the primary diagnosis, a respiratory-related emergency department visit, prescription for acute oral corticosteroids, and/or an acute exacerbation documented in the 
electronic medical record. bStandardized mean difference >10% for comparison of never high and persistently high. cDefined as the absence of both an acute respiratory event and 
a respiratory-related outpatient visit. dDefined as attainment of Risk Domain Asthma Control and an average daily dose of ≤ 200-μg salbutamol/≤ 500-μg terbutaline. eDefined as 
the absence of frequent (≥ 2) oral corticosteroid course prescriptions, respiratory hospital admission, emergency department visit, or poor symptom control. 
Abbreviation: SD, standard deviation.
Journal of Asthma and Allergy 2021:14                                                                                            https://doi.org/10.2147/JAA.S306416                                                                                                                                                                                                                       
DovePress                                                                                                                         
737
Dovepress                                                                                                                                                             Tran et al
































































risk. It is interesting to note that the proportion of patients 
who were current or former smokers in this study is 
similar between CPRD and OPCRD but greater than in 
previous UK studies,19,21 which may reflect the 
requirement for having at least 3 BEC measurements. 
Patients with asthma who were current or former smokers 
may have more check-up visits and, thus, more blood 
eosinophil measurements performed. Further research is 
Table 6 Health Care Resource Utilization During the Outcome Year by Longitudinal Eosinophil Pattern (Univariable Analysis)
Parameter Never High (N = 32,894) Intermittently High  
(N = 27,966)
Persistently High  
(N = 9446)
All-cause GP consultationsb 12.54 ± 9.56 13.17 ± 10.39 11.71 ± 8.86
Respiratory-related GP consultations 4.59 ± 4.95 4.73 ± 5.10 4.70 ± 5.01
All-cause outpatient visits 3.76 ± 6.01 4.16 ± 7.05 3.51 ± 6.05
Respiratory outpatient visits 0.10 ± 0.71 0.13 ± 0.91 0.13 ± 0.89
All-cause emergency department visits 0.45 ± 1.48 0.48 ± 1.32 0.42 ± 1.06
Patients with ≥4 visits, n (%) 589 (1.8) 608 (2.2) 163 (1.7)
Respiratory emergency department visits 0.04 ± 0.51 0.05 ± 0.32 0.04 ± 0.27
Hospital admissions with asthma as the primary diagnosis 0.01 ± 0.19 0.02 ± 0.23 0.01 ± 0.20
Hospital admissions with a respiratory condition as the primary 
diagnosis
0.03 ± 0.29 0.05 ± 0.35 0.04 ± 0.28
Patients with ≥1 overnight hospitalization with asthma as the 
primary diagnosis, n
170 233 80
Length of staya,b 8.0 ± 12.2 6.9 ± 11.2 4.7 ± 7.6
Patients with ≥1 overnight stay with a respiratory condition as 
the primary diagnosis, n
1085 1339 391
Length of staya,b 8.8 ± 14.7 9.5 ± 16.0 6.5 ± 10.2
Notes: Data are means ± standard deviations unless otherwise specified. P < 0.001 for tests of independence/equality of populations for all categories except respiratory- 
related GP consultations (P =0.01) and length of stay for patients with ≥ 1 overnight hospitalization with asthma as the primary diagnosis (P =0.06). aStandardized mean 
difference (SMD) >10% for comparison of never high and persistently high. bSMD >10% for comparison of intermittently high and persistently high. 
Abbreviation: GP, general practitioner.
Figure 4 Association between longitudinal eosinophil patterns and exacerbations in the outcome year by smoking status. 
Abbreviation: CI, confidence interval.
https://doi.org/10.2147/JAA.S306416                                                                                                                                                                                                                                   
DovePress                                                                                                                                                      
Journal of Asthma and Allergy 2021:14 738
Tran et al                                                                                                                                                              Dovepress
































































needed to understand the interactions between smoking, 
BEC elevations, and exacerbation risk.
Unlike exacerbation rates, no appreciable differences 
in other measures of asthma control were observed among 
blood eosinophil pattern groups. Notably, less than one- 
quarter of patients across eosinophil groups achieved full 
asthma control during the outcome year. Differences in 
asthma treatment during the baseline year were minimal. 
Interestingly, 22% to 26% of patients were prescribed 
OCS, a small percent at moderate or high doses (mean 
daily dose >5 mg), despite the associated risk for acute and 
chronic adverse events.6,35 These data add to the large 
body of literature indicating that a considerable proportion 
of patients in clinical practice have suboptimal asthma 
symptom control, many of whom would benefit from 
referral to a specialist for evaluation and management.36,37
In general, HCRU did not appreciably differ among 
patients in the 3 eosinophil elevation pattern groups. For 
patients with an asthma-related hospitalization, the length 
of stay was shorter for patients with persistent BEC eleva-
tions, particularly in comparison with patients in the never 
high group. This observation suggests that persistently 
high BECs may represent a distinct subset of patients 
within the eosinophilic endotype in whom eosinophilia 
dominates the etiology and, hence, respond rapidly to 
currently available eosinophil-targeted therapies. It should 
be noted, however, that the persistently high group had 
a lower comorbidity burden compared with the intermit-
tently high group, which has been shown to affect asthma- 
related hospital length of stay.38 Evaluation of treatment 
response in patients with differing eosinophil elevation 
patterns is warranted to better understand this patient 
subgroup.
Identifying a patient’s asthma endotype has significant 
relevance to clinical practice. As the accumulated evidence 
suggests, eosinophil elevations indicate increased risk for 
asthma exacerbations and adverse outcomes,13–19 thus dis-
tinguishing a patient population in need of further mon-
itoring and intervention. Patients with eosinophil 
elevations may also be candidates for biologic therapies 
targeting interleukin 5 or the interleukin-5 receptor. In 
clinical practice, however, measurement of BECs has not 
been incorporated as a universal facet of asthma manage-
ment. Indeed, a prior analysis of data from OPCRD and 
CPRD found that only 52% of patients with asthma had 
BECs recorded in the EMR.15 Regular assessment of 
asthma endotype, including measurement of biomarker 
concentrations, is needed to improve implementation of 
individualized, targeted asthma management.
A major strength of this study was that it utilized 
a large data set in a first-of-its-kind analysis of longitudi-
nal, repeated blood eosinophil measurements, which 
allowed for evaluation of the heretofore unexamined rela-
tionship between eosinophil elevation patterns and exacer-
bations. There are several limitations that affect the 
interpretation of these analyses. Full blood count measure-
ments are not routinely performed (every 1 to 2 years) and 
are generally requested for a specific medical reason; 
therefore, ascertainment bias in the types of patients for 
whom BEC data were available cannot be excluded, and 
the study population may not be fully representative of the 
broader population of patients with asthma. In the OPCRD 
data set, for example, 43% of patients with a diagnostic 
code for asthma were not eligible for inclusion in the 
analysis due to lack of a BEC measurement. Comparable 
statistics were not available for the CPRD data set. Both 
the OPCRD and CPRD data sets comprise information 
collected for clinical and routine use rather than specifi-
cally for research purposes. Although extensive quality 
control and validity checks are conducted on the practice 
level, the validity and completeness of individual patient 
records may be limited. Among the possible influences on 
BECs, we cannot exclude the potential effect of ICS, 
which was used by the majority of patients in each BEC 
category. Interestingly, 85% of patients were receiving ICS 
in the persistently high group, suggesting that ICS use is 
insufficient to lower BECs to ≤300 cells/µL for these 
patients. We also did not evaluate the prevalence of eosi-
nophilic esophagitis among BEC groups, despite its asso-
ciation with asthma, because of the diagnostic challenges 
and rarity of the condition. A variable that was not avail-
able for analysis in the data sets was the time of day of 
BEC measurement. Circadian variations have been 
observed for BECs.39,40 The magnitude of daily variation 
is modest; therefore, the number of instances where the 
time of day made the difference between a value above or 
below 300 cells/µL is likely small. Moreover, geometric 
mean BECs at the index date were 125.9 ± 2.0 cells/µL in 
the never high group and 501.2 ± 1.6 cells/µL in the 
persistently high group, indicating that measurements in 
these groups were generally not close to the 300 cells/µL 
threshold. The group most likely to be affected were 
patients in the intermittently high group, for whom varia-
bility in measurement is expected.
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These data validate the use of blood eosinophil measure-
ments to characterize a patient population at increased risk 
for severe asthma exacerbations. The consistency in risk 
elevation between the persistently high and intermittently 
high groups suggests that in patients with a single or 
multiple BEC measurements, 1 or more elevated BEC is 
sufficient to characterize a patient as having eosinophilic 
asthma, thus affirming the validity of categorizing patients 
in clinical practice, clinical trials, and real-world studies 
using the highest recorded BEC. Conversely, a single eosi-
nophil measurement ≤300 cells/µL cannot rule out the 
potential of having eosinophilic asthma. For these patients, 
additional measurement of BECs in clinical practice is 
needed to increase the identification and appropriate man-
agement of patients with eosinophilic asthma.
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